ABBV AbbVie Inc. Stock Quote

ABBV [NYSE]

Healthcare | Drug Manufacturers - General | USA

Index	S&P 500	P/E	29.18	EPS (ttm)	3.71	Insider Own	0.10%	Shs Outstand	1.77B	Perf Week	-0.11%
Market Cap	190.84B	Forward P/E	7.76	EPS next Y	13.98	Insider Trans	-5.84%	Shs Float	1.76B	Perf Month	1.18%
Income	6.60B	PEG	6.32	EPS next Q	3.23	Inst Own	68.80%	Short Float	0.77%	Perf Quarter	-7.77%
Sales	53.73B	P/S	3.55	EPS this Y	-48.50%	Inst Trans	0.15%	Short Ratio	1.92	Perf Half Y	-1.49%
Book/sh	7.11	P/B	15.25	EPS next Y	10.83%	ROA	4.40%	Target Price	127.01	Perf Year	28.68%
Cash/sh	4.89	P/C	22.19	EPS next 5Y	4.62%	ROE	48.30%	52W Range	79.11 - 121.53	Perf YTD	1.18%
Dividend	5.20	P/FCF	17.77	EPS past 5Y	-2.80%	ROI	12.70%	52W High	-10.80%	Beta	0.80
Dividend %	4.80%	Quick Ratio	0.80	Sales past 5Y	14.90%	Gross Margin	65.70%	52W Low	37.04%	ATR	1.72
Employees	48000	Current Ratio	0.90	Sales Q/Q	33.90%	Oper. Margin	28.90%	RSI (14)	45.90	Volatility	1.26% 1.57%
Optionable	Yes	Debt/Eq	6.53	EPS Q/Q	191.90%	Profit Margin	12.30%	Rel Volume	0.79	Prev Close	107.45
Shortable	Yes	LT Debt/Eq	5.91	Earnings	Oct 29 BMO	Payout	133.00%	Avg Volume	7.12M	Price	108.41
Recom	2.00	SMA20	-0.17%	SMA50	-2.96%	SMA200	-2.54%	Volume	5,627,072	Change	0.89%

Jul-27-21

Resumed

Truist

Buy

$118

Apr-07-21

Resumed

RBC Capital Mkts

Outperform

$135

Nov-10-20

Resumed

Bernstein

Outperform

$120

Sep-29-20

Initiated

Berenberg

Hold

$98

Jun-23-20

Upgrade

Atlantic Equities

Neutral → Overweight

$115

Jun-09-20

Upgrade

Wolfe Research

Peer Perform → Outperform

Jun-02-20

Upgrade

Argus

Hold → Buy

$115

May-18-20

Resumed

BofA/Merrill

Neutral

$95

May-12-20

Upgrade

JP Morgan

Neutral → Overweight

$105

May-11-20

Resumed

Morgan Stanley

Overweight

$95

Apr-20-20

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

$79 → $93

Mar-23-20

Downgrade

Societe Generale

Buy → Hold

Feb-27-20

Initiated

Barclays

Equal Weight

$97

Feb-06-20

Initiated

Mizuho

Buy

Jan-07-20

Initiated

RBC Capital Mkts

Sector Perform

$86

Dec-26-19

Reiterated

Cowen

Outperform

$90 → $98

Sep-26-19

Upgrade

Citigroup

Neutral → Buy

$87 → $90

Aug-20-19

Upgrade

Piper Jaffray

Neutral → Overweight

$80

Jun-27-19

Upgrade

Wolfe Research

Underperform → Peer Perform

Jun-26-19

Upgrade

SVB Leerink

Mkt Perform → Outperform

$88

Oct-20-21 03:49PM	AbbVie Stock Is Making A Comeback On Inflammatory Drugs Is It A Buy Now? Investor's Business Daily
12:35PM	11 High Dividend Stocks Picked by Billionaire Gabelli Insider Monkey
Oct-19-21 03:10PM	3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat Benzinga
12:31PM	20 Safe Dividend Stocks to Quit Your 9 to 5 Job Insider Monkey
06:10AM	3 Leading Healthcare Stocks to Buy in 2021 and Beyond Motley Fool
Oct-18-21 05:45PM	AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know Zacks
05:58AM	3 High-Yield Dividend Stocks I'm Not Selling Anytime Soon Motley Fool
Oct-16-21 10:45AM	3 Best Dividend Stocks for Retirement Motley Fool
06:45AM	2 Buffett Stocks to Buy and Hold Forever Motley Fool
Oct-15-21 08:35AM	AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU) PR Newswire
07:00AM	Want More Monthly Income? Invest in These 3 Stocks Motley Fool
Oct-11-21 05:45PM	AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know Zacks
11:45AM	This is Why AbbVie (ABBV) is a Great Dividend Stock Zacks
08:42AM	Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Awareness PR Newswire
Oct-08-21 05:36AM	10 Best Big Pharma Stocks to Buy Now Insider Monkey
Oct-07-21 01:22PM	Health Canada Approves the Use of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Moderate to Severe Atopic Dermatitis CNW Group
12:49PM	AbbVie Touts Additional Rinvoq Data In Inflammatory Spinal Arthritis Benzinga
10:30AM	Why AbbVie Stock Sank in September Motley Fool
10:24AM	10 Dividend Stocks to Increase Your Monthly Income Insider Monkey
08:38AM	AbbVie Higher on Rinvoq Trial Progress to Treat Spinal Arthritis TheStreet.com
08:16AM	AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis PR Newswire
08:15AM	AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis PR Newswire
Oct-06-21 11:25AM	Biohaven (BHVN) Q3 Nurtec Preliminary Sales Top Expectations Zacks
Oct-05-21 08:00AM	AbbVie to Host Third-Quarter 2021 Earnings Conference Call PR Newswire
Oct-04-21 05:45PM	AbbVie (ABBV) Stock Moves -0.33%: What You Should Know Zacks
04:38PM	Botox war: East Bay challenger sued by maker of blockbuster cosmetic toxin American City Business Journals
06:18AM	Investing in Pharma Stocks? Watch for These 2 Red Flags Motley Fool
Oct-02-21 06:06PM	AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021 PR Newswire
Oct-01-21 09:18AM	Pharma Stock Roundup: MRK to Buy XLRN, ABBV Gets FDA Nod for Migraine Drug & More Zacks
Sep-30-21 09:45AM	AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress PR Newswire
08:30AM	AbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress PR Newswire
Sep-29-21 10:08AM	AbbVie's (ABBV) Migraine Prevention Drug Qulipta Gets FDA Nod Zacks
08:45AM	Here's How a New Investor Started Her Portfolio With Just 10 Top Stocks Motley Fool
08:37AM	FDA Gives Nod To First Oral CGRP Receptor To Prevent Migraine From AbbVie Benzinga
08:13AM	The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga
07:45AM	Here's Why AbbVie Is a Great Healthcare Stock for Long-Term Investors Motley Fool
Sep-28-21 07:05PM	UPDATE 1-U.S. FDA approves AbbVie's migraine prevention drug Reuters
06:42PM	FDA Approves QULIPTA (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine PR Newswire
08:07AM	3 Top Stocks for Retirees Motley Fool
Sep-27-21 05:45PM	AbbVie (ABBV) Gains As Market Dips: What You Should Know Zacks
08:30AM	Americans are Frustrated by Unexpected Blurry Near Vision Issues, a New Survey Reveals PR Newswire
06:45AM	Could AbbVie's New Collaboration Be a Blockbuster? Motley Fool
06:06AM	3 High-Yield Dividend Stocks Warren Buffett Loves Motley Fool
Sep-25-21 10:55AM	10 Best Stocks for Dividends Insider Monkey
06:55AM	Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal Motley Fool
Sep-24-21 01:16PM	Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug Benzinga
11:45AM	AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy? Zacks
08:27AM	Pharma Stock Roundup: PFE Booster Jab Gets FDA Nod, JNJ's New Data on COVID-19 Shot Zacks
Sep-23-21 08:45AM	AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress PR Newswire
06:03AM	3 Relatively Safe Pharma Stocks You Can Buy Right Now Motley Fool
Sep-22-21 01:24PM	AbbVie Stock Gets Pounded; How To Make A 15% Annualized Return With A Covered Call Investor's Business Daily
06:03AM	Option Trade: Increase Your Income With This Covered Call Strategy Investor's Business Daily Video
Sep-21-21 10:19PM	Is AbbVie (ABBV) A Good Stock To Buy? Insider Monkey
12:07PM	AbbVie (ABBV) Files for Skyrizi in Crohn's Disease With FDA Zacks
Sep-20-21 05:45PM	AbbVie (ABBV) Stock Moves -1.23%: What You Should Know Zacks
09:10AM	AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease PR Newswire
Sep-19-21 11:01AM	Is AbbVie a Bad News Buy? Motley Fool
09:31AM	Cramer: Using Short-Term Moves to Tweak Your Portfolio TheStreet.com
Sep-18-21 05:57AM	AbbVie's Pain Is Sanofi's and Regeneron's Gain Motley Fool
Sep-17-21 01:17PM	Why BeiGene's Shares Jumped on Friday Motley Fool
09:11AM	AbbVie (ABBV) Files for Rinvoq in Ulcerative Colitis in US & EU Zacks
07:40AM	Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win Zacks
Sep-16-21 12:42PM	AbbVie Submits Upadacitinib Applications In US, Europe For Ulcerative Colitis Benzinga
09:05AM	2 Embarrassingly Cheap Dividend Stocks to Buy Motley Fool
08:00AM	AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis PR Newswire
Sep-15-21 11:00AM	Is AbbVie's 4.9% Dividend Yield Safe? Motley Fool
Sep-14-21 05:45PM	AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know Zacks
11:21AM	AbbVie Selloff Overdone, Stock Remains Undervalued: BMO TheStreet.com
10:55AM	REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie Zacks
10:45AM	AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy Zacks
10:24AM	5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal Zacks
07:52AM	REGENXBIO (RGNX) Moves 31.2% Higher: Will This Strength Last? Zacks
Sep-13-21 04:06PM	Regenxbio Stock Catapults To 7-Month High On AbbVie's $1.75 Billion Bet On Gene Therapy Investor's Business Daily
02:40PM	Why Regenxbio Stock Is Way Up Today Motley Fool
10:57AM	Why Regenxbio Shares Are Trading Higher Today Benzinga
10:10AM	AbbVie Nabs Eye Disease Gene Therapy From Regenxbio for Up to $1.8 Billion Barrons.com
08:39AM	AbbVie, RegenXBio Ink $1.75B Retinal Gene Therapy Collaboration Benzinga
08:25AM	AbbVie's deal to develop Regenxbio's investigational gene therapy could be worth $1.8 billion MarketWatch
07:13AM	UPDATE 1-AbbVie, Regenxbio enter deal to develop retinal disease therapy Reuters
06:30AM	AbbVie and REGENXBIO Announce Eye Care Collaboration PR Newswire
Sep-10-21 12:19PM	Downward Pressures and Flat Earnings Outweigh the AbbVie Inc.'s (NYSE:ABBV) Dividend Yield Simply Wall St.
10:27AM	AbbVie Declares Quarterly Dividend PR Newswire
09:55AM	3 Stocks to Watch in September Motley Fool
09:00AM	AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021 PR Newswire
Sep-09-21 11:30AM	Could This Label Expansion Be a Blockbuster for AbbVie's Shareholders? Motley Fool
08:00AM	AbbVie to Present at the Morgan Stanley Healthcare Conference PR Newswire
07:00AM	Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet PR Newswire
07:00AM	Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkins Lymphoma (B-NHL) Published in The Lancet Business Wire
Sep-08-21 05:45PM	AbbVie (ABBV) Gains As Market Dips: What You Should Know Zacks
11:45AM	Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio Zacks
09:10AM	AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress PR Newswire
Sep-07-21 01:31PM	Top Analyst Reports for Facebook, AbbVie & 3M Zacks
Sep-06-21 11:47AM	AbbVie Could Be a Good Defensive Play TheStreet.com
Sep-03-21 10:06AM	Pharma Stock Roundup: New Warning Order by FDA for JAK Drugs, & Pipeline Updates Zacks
06:21AM	Are Investors Undervaluing AbbVie Inc. (NYSE:ABBV) By 48%? Simply Wall St.
Sep-02-21 03:04PM	AbbVie Stock Dropped After FDA Warning. Analysts Say Selloff Is Overblown. Barrons.com
01:34PM	7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In InvestorPlace
11:34AM	AbbVie (ABBV) Stock Down as FDA Issues New Warning for Rinvoq Zacks
09:17AM	FDA Orders Warnings on Pfizer, Lilly, AbbVie JAK Drug Labels Zacks
08:34AM	FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know Benzinga

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sorg Elaine K.	SVP, US Commercial Operations	Aug 23	Option Exercise	114.36	7,080	809,669	18,675	Aug 25 06:08 PM
Sorg Elaine K.	SVP, US Commercial Operations	Aug 23	Sale	120.00	13,080	1,569,600	11,595	Aug 25 06:08 PM
Strom Carrie C	SVP & Pres Global Allerg Aesth	Aug 23	Sale	120.00	5,057	606,840	51,047	Aug 25 06:08 PM
SALEKI-GERHARDT AZITA	EVP, Operations	May 24	Option Exercise	34.93	86,920	3,036,230	203,204	May 26 05:20 PM
SALEKI-GERHARDT AZITA	EVP, Operations	May 24	Sale	116.29	86,920	10,108,033	116,284	May 26 05:20 PM
Strom Carrie C	SVP & Pres Global Allerg Aesth	May 03	Option Exercise	41.39	4,184	173,176	63,409	May 05 04:23 PM
Strom Carrie C	SVP & Pres Global Allerg Aesth	May 03	Sale	112.40	4,184	470,282	59,225	May 05 04:23 PM
GONZALEZ RICHARD A	Chairman of the Board and CEO	Mar 02	Option Exercise	54.86	170,113	9,332,399	546,710	Mar 02 08:27 PM
GONZALEZ RICHARD A	Chairman of the Board and CEO	Mar 01	Sale	108.61	170,113	18,476,204	376,597	Mar 02 08:27 PM
Stewart Jeffrey Ryan	SVP, US Commercial Operations	Mar 01	Sale	108.59	13,773	1,495,576	50,969	Mar 02 08:26 PM
RICHMOND TIMOTHY J.	EVP, Chief HR Officer	Mar 01	Sale	108.59	19,514	2,119,041	0	Mar 02 08:31 PM
Sorg Elaine K.	SVP, US Commercial Operations	Mar 01	Sale	108.61	8,440	916,642	17,595	Mar 02 08:30 PM
Sorg Elaine K.	SVP, US Commercial Operations	Feb 22	Option Exercise	89.78	20,195	1,813,052	52,946	Feb 24 06:28 PM
Sorg Elaine K.	SVP, US Commercial Operations	Feb 22	Sale	104.72	20,195	2,114,732	32,751	Feb 24 06:28 PM
Stewart Jeffrey Ryan	EVP, Commercial Operations	Dec 29	Option Exercise	51.42	25,290	1,300,412	76,259	Dec 31 01:15 PM
Stewart Jeffrey Ryan	EVP, Commercial Operations	Dec 29	Sale	105.00	25,290	2,655,450	50,969	Dec 31 01:15 PM
RICHMOND TIMOTHY J.	EVP, Chief HR Officer	Nov 27	Option Exercise	51.42	51,990	2,673,326	51,990	Dec 01 05:22 PM
RICHMOND TIMOTHY J.	EVP, Chief HR Officer	Nov 27	Sale	105.00	51,990	5,458,950	0	Dec 01 05:22 PM
Gosebruch Henry O	EVP, Chief Strategy Officer	Nov 20	Sale	99.38	40,000	3,975,046	20,006	Nov 24 05:34 PM
ALBAN CARLOS	Vice Chairman	Nov 16	Option Exercise	35.88	115,830	4,155,980	230,729	Nov 18 05:04 PM
ALBAN CARLOS	Vice Chairman	Nov 16	Sale	100.00	115,830	11,583,000	114,899	Nov 18 05:04 PM
GONZALEZ RICHARD A	Chairman of the Board and CEO	Nov 12	Option Exercise	57.12	194,154	11,089,858	512,796	Nov 12 05:54 PM
GONZALEZ RICHARD A	Chairman of the Board and CEO	Nov 12	Sale	97.10	194,154	18,851,790	318,642	Nov 12 05:54 PM
SALEKI-GERHARDT AZITA	EVP, Operations	Nov 10	Sale	98.00	17,426	1,707,748	96,441	Nov 12 05:56 PM
GONZALEZ RICHARD A	Chairman of the Board and CEO	Nov 09	Sale	95.74	37,450	3,585,463	318,642	Nov 12 05:54 PM
SALEKI-GERHARDT AZITA	EVP, Operations	Nov 04	Sale	93.61	4,800	449,328	109,067	Nov 06 04:29 PM
SEVERINO MICHAEL	Vice Chairman	Nov 04	Sale	93.61	90,679	8,488,461	67,281	Nov 06 04:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience